APIM Therapeutics is developing a series of proprietary Protein Protein Interaction (PPI) blocking peptides targeting complexes formed between PCNA (Proliferating Cell Nuclear Antigen) and proteins bearing a novel PCNA-interacting Peptide Motif called APIM (AlkB homolog 2 PCNA Interacting Motif). These compounds are particularly relevant for the treatment of hyper-proliferative disorders such as cancer.

Our therapeutic candidate, ATX-101, is a first-in class PCNA/APIM PPI blocking compound that has recently reached the clinical stage. ATX-101 is being developed for the treatment of several cancer indications either alone or in combination with selected anti-cancer agents. A snapshot of the drug pipeline of APIM Therapeutics is presented below. The company has a strong interest in multiple myeloma and bladder cancer (advanced and localized/superficial). Other indications/combinations are also of further interest for future applications.

Drug Pipeline

To access more information on the mechanism of action and a summary of key data, follow this link.

Drug Pipeline

Mechanism of Action & Key Data


APIM Therapeutics‘s Flyer

APIM THerapeutics Snapshot Download this pdf for a summary of the company and contact information. View also recent publications and scientific posters in our Media Center section.